Vandervoort Adam C 4
4 · Teladoc Health, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Teladoc (TDOC) Chief Legal Officer Adam Vandervoort Exercises Awards and Sells Shares
What Happened
Adam C. Vandervoort, Teladoc Health’s Chief Legal Officer and Secretary, reported conversions/vestings of performance and restricted stock units and an open‑market sale. The filing shows he converted/received a number of PSUs/RSUs (totaling tens of thousands of underlying shares from multiple awards) and on March 2, 2026 sold 27,083 shares in the open market at $5.12 per share for proceeds of $138,584. Several converted shares were surrendered with $0 proceeds to satisfy tax withholding obligations.
Key Details
- Transaction dates: primary activity on Feb 27, 2026 (multiple conversions/vestings) and Mar 1–2, 2026 (additional grant on Mar 1; sale on Mar 2). Filing date: Mar 3, 2026 (appears timely).
- Open-market sale: 27,083 shares sold on 2026-03-02 at $5.12, proceeds $138,584.
- Conversions/exercises (listed as “M” derivative exercises) on 2026-02-27 total 49,590 shares converted (4,418 + 5,350 + 36,610 + 1,510 + 1,702). Matching $0.00 disposition entries indicate shares were surrendered to cover tax withholding.
- Awards/grants: reported acquisitions include 5,107 shares on 2026-02-27 and 181,661 shares on 2026-03-01 (reported as awards/earned performance stock units).
- Footnotes: PSUs and RSUs convert one‑for‑one into common stock (F1,F2,F8,F12). One‑third of certain awards vested on Mar 1, 2026, with remaining amounts vesting in eight substantially equal quarterly installments (F10, F11, F13). F3 notes shares were sold to cover tax withholding. F9 indicates performance awards reflect 2025 financial results.
- Shares owned after the transactions: not specified in the data provided.
Context
- These filings mainly reflect vesting/conversion of restricted and performance awards and routine tax-withholding sales, not an outright open-market buy. The March 2 open‑market sale produced modest proceeds (~$138.6k).
- The zero‑proceeds dispositions tied to the derivative entries indicate a cashless settlement or shares withheld/surrendered to satisfy tax withholding rather than a market sale.
- Filing date (Mar 3, 2026) appears to be within the required reporting window for the listed transaction dates.
Insider Transaction Report
Form 4
Vandervoort Adam C
CHIEF LEGAL OFFICER, SECRETARY
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-27+4,418→ 85,150 total - Exercise/Conversion
Common Stock
[F1]2026-02-27+5,350→ 90,500 total - Exercise/Conversion
Common Stock
[F1]2026-02-27+36,610→ 127,110 total - Exercise/Conversion
Common Stock
[F2]2026-02-27+1,510→ 128,620 total - Exercise/Conversion
Common Stock
[F2]2026-02-27+1,702→ 130,322 total - Sale
Common Stock
[F3]2026-03-02$5.12/sh−27,083$138,584→ 103,239 total - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-02-27−4,418→ 0 total→ Common Stock (4,418 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F5]2026-02-27−5,350→ 21,400 total→ Common Stock (5,350 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F6]2026-02-27−36,610→ 73,222 total→ Common Stock (36,610 underlying) - Exercise/Conversion
Performance Stock Units
[F2][F7]2026-02-27−1,510→ 0 total→ Common Stock (1,510 underlying) - Award
Performance Stock Units
[F8][F9][F10]2026-02-27+5,107→ 5,107 total→ Common Stock (5,107 underlying) - Exercise/Conversion
Performance Stock Units
[F2][F11]2026-02-27−1,702→ 3,405 total→ Common Stock (1,702 underlying) - Award
Restricted Stock Units
[F12][F13]2026-03-01+181,661→ 181,661 total→ Common Stock (181,661 underlying)
Footnotes (13)
- [F1]Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
- [F10]The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F11]On March 1, 2026, the reporting person earned 5,107 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F12]Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
- [F13]One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F2]Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
- [F3]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
- [F4]On March 3, 2023, the reporting person was granted 53,013 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F5]On March 19, 2024, the reporting person was granted 64,200 restricted stock units, vesting one-third on March 19, 2025, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.
- [F6]On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F7]On March 1, 2024, the reporting person earned 18,067 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.
- [F8]Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
- [F9]Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.
Signature
/s/ Adam C. Vandervoort|2026-03-03